Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis b carriers: A review of the problem

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 394-398

  Liang, Raymond ^a   Lau, George K K ^a   Kwong, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; FAMCICLOVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE;

BLOOD DONOR; BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER DISEASE; PRIORITY JOURNAL; REVIEW; VIRUS CARRIER; VIRUS REACTIVATION;

EID: 0032894969     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.394     Document Type: Review

References (50)

1. Lok ASF, Lai CL, Wu PC: Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 126:492-499, 1987
2. Lok ASF: Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 10:46-52, 1992
3. Wands JR: Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet 2:979, 1975 (letter)
4. Lok ASF, Liang RHS, Chiu EKW, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 100:182-188, 1991
5. Liang R, Lok ASF, Lai CL, et al: Hepatitis B infection in patients with lymphomas. Hematol Oncol 8:261-270, 1990
6. Lau JYN, Lai CL, Lin HJ, et al: Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 36:47-54, 1989
7. Kumagai K, Takagi T, Nakamura S, et al: Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan. Ann Oncol 8:S107-S109, 1997 (suppl 1)
8. Nakamura Y, Motokura T, Fujita A, et al: Severe hepatitis related to chemotherapy in hepatitis B carriers with hematological malignancies. Cancer 78:2210-2215, 1996
9. Chazouilleres O, Mamish D, Kim M, et al: "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 343:142-146, 1994
10. Lok ASF, Wu PC, Lai CL, et al: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102:2091-2097, 1992
11. Brook MG, Karayiannis P, Thomas HC: Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10:761-763, 1989
12. Luscombe CA, Locarnini SA: The mechanism of action of anti-viral agents in chronic hepatitis B. Viral Hepatol Rev 2:1-35, 1995
13. Lai CL, Ching CK, Tung AK, et al: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 25:241-244, 1997
14. Dienstag JL, Perrillo RP, Schiff ER, et al: A preliminary trial of lamivudine for chrome hepatitis B infection. N Engl J Med 333:1657-1661, 1995
15. Colledge D, Locarnini S, Shaw T: Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir. Hepatology 26:216-223, 1997
16. Main J, Brown JL, Howells C, et al: A double blind placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepatol 3:211-215, 1996
17. Trepo C, Jezed P, Atkinson GE, et al: Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study. Hepatology 24:188A, 1996 (abstr)
18. Clark FL, Drummond MW, Chambers S, et al: Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 9:385-387, 1998
19. Lau GKK, Liang RHS, Chiu EKW, et al: Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case-controlled study. Bone Marrow Transplant 19:795-799, 1997
20. Caselitz M, Link H, Hein R, et al: Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 27:572-577, 1997
21. Chen PM, Fan S, Liu CJ, et al: Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 49:708-713, 1990
22. Chen PM, Liu JH, Fan FS, et al: Liver disease after bone marrow transplantation: The Taiwan experience. Transplantation 59:1139-1143, 1995
23. Lok ASF, Liang RHS, Chung HT: Recovery from hepatitis B. Ann Intern Med 116:957, 1992 (letter)
24. Ilan Y, Nagler A, Adler R, et al: Ablation of persistent hepatitis B by BMT from a hepatitis B immune donor. Gastroenterology 104:1818-1821, 1993
25. Lau GKK, Lok ASF, Liang RHS, et al: Clearance of HBsAg after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology 25:1497-1501, 1997
26. Locasciulli A, Albert A, de Bock R, et al: Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: A survey from the European Bone Marrow Transplantation (EBMT) Group - Infectious Diseases Working Party. Bone Marrow Transplant 14:833-837, 1994
27. Martin BA, Rowe JM, Kouides PA, et al: Hepatitis B reactivation following allogeneic bone marrow transplantation: A case report and review of the literature. Bone Marrow Transplant 15:145-148, 1995
28. Lau GKK, Chen F, Liang RHS. Reactivation of chronic HBV infection after bone marrow transplantation. Hepatology 24:286A, 1996 (abstr)
29. Reed EC, Myerson D, Corey L, et al: Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 77:195-200, 1991
30. Locasciulli A, Alberti A, Bandini G, et al: Allogeneic bone marrow transplantation from HBsAg+ donors: A multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 86:3236-3240, 1995
31. Chen PM, Fan S, Liu JH, et al: Reactivation of hepatitis B virus in two chronic GVHD patients after transplant. Int J Hematol 58:183-188, 1993
32. Forbes GM, Davis JM, Hermann RP, et al: Liver disease complicating bone marrow transplantation: A clinical audit. J Gastroenterol Hepatol 10:1-7, 1995
33. Appleton AL, Sviland L, Peiris JS, et al: Role of target organ infection with cytomegalovirus in the pathogenesis of graft-versus-host disease. Bone Marrow Transplant 15:557-561, 1995
34. Frickhofen N, Wiesneth M, Jainta C, et al: Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 83:1998-2004, 1994
35. Appleton AL, Sviland L: Pathogenesis of GVHD: Role of herpes viruses. Bone Marrow Transplant 11:349-355, 1993
36. Ferrara JL: Cytokine inhibitors and graft-versus-host disease. Ann NY Acad Sci 770:227-236, 1995
37. Ayash LJ, Hunt M, Antman K, et al: Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphoma. J Clin Oncol 8:1699-1706, 1990
38. Lau GKK, Liang R, Wu PC, et al: Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 28:359-368, 1998
39. Lau GKK, Lai CL, Lee CK, et al: Clinical and serological outcome of allogeneic bone marrow transplantation from HBsAg positive donors. Gastroenterology 110:A1246, 1996 (abstr)
40. Markowitz JS, Martin P, Conrad AJ, et al: Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585-589, 1998
41. Daily J, Werner B, Soiffer R, et al: IGIV: A potential role for hepatitis B prophylaxis in the bone marrow peritransplant period. Bone Marrow Transplant 21:739-742, 1998
42. Picardi M, Selleri C, De Rosa G, et al: Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 21:1267-1269
43. Fan FS, Tzeng CH, Yeh HM, et al: Reverse seroconversion of hepatitis B virus infectious status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant 10:189-191, 1992
44. Celis E, Kung PC, Chang TW, et al: Hepatitis B virus-reactive human T lymphocyte clones: Antigen specificity and helper function for antibody synthesis. J Immunol 132:1511-1516, 1984
45. Penna A, Chisari FV, Bertoletti A, et al: Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174:1565-1570, 1991
46. Missale G, Redeker A, Person J: HLA-A31 and Aw68 restricted cytotoxic T cell response to a single hepatitis B virus nucleocapsid during acute viral hepatitis. J Exp Med 177:751-762, 1993
47. Bertoletti A, Ferrari FV, Fiaccadori F, et al: HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 88:10445-10449, 1991
48. Rehermann B, Lau D, Hoofnagle JH, et al: Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655-1665, 1996
49. Ilan Y, Nagler A, Adler R, et al: Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 18:246-252, 1993
50. Lau GKK, Liang R, Lee CK: Clearance of persistent hepatitis B virus infections in Chinese bone marrow transplant recipients from anti-HBc+/anti-HBs+ BMT donors. J Infect Dis (in press)